IMVT-1402 Shows Strong Preliminary Efficacy in Rheumatoid Arthritis; Batoclimab Development Discontinued

summarizeSummary

Immunovant reported strong preliminary Phase 2b results for IMVT-1402 in D2T RA and discontinued batoclimab development, focusing resources on its lead asset. The company also secured a cash runway through the potential commercial launch of IMVT-1402 in Graves' Disease.

check_boxKey Events

• Strong Preliminary IMVT-1402 D2T RA Results

  Preliminary Week 16 data from a potentially registrational trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) showed high ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% respectively, with no new safety signals.

• Batoclimab Development Discontinued

  Immunovant discontinued further development of its first-generation antibody, batoclimab, across all indications after it failed to meet primary endpoints in two Phase 3 thyroid eye disease (TED) studies.

• Extended Cash Runway

  Existing cash and cash equivalents of $902.1 million are expected to fund operations through the potential commercial launch of IMVT-1402 in Graves' Disease, supported by a $543.7 million underwritten offering in December 2025.

• Strategic Focus on IMVT-1402

  The company is now fully focused on advancing IMVT-1402, with ongoing registrational trials in Graves' Disease, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Sjögren's Disease, and a proof-of-concept trial in Cutaneous Lupus Erythematosus.

auto_awesomeAnalysis

Immunovant's annual report highlights significant progress in its lead asset, IMVT-1402, with strong preliminary Week 16 results from a potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA). The trial reported high ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% respectively, with a favorable safety profile. This positive clinical data for a key program is a major de-risking event. Concurrently, the company announced the discontinuation of its first-generation anti-FcRn antibody, batoclimab, across all indications following its failure to meet primary endpoints in two Phase 3 thyroid eye disease (TED) studies. This strategic pivot allows Immunovant to fully focus resources on the more promising IMVT-1402 pipeline. Financially, the company reported a net loss of $505.6 million for the fiscal year but has extended its cash runway to fund operations through the potential commercial launch of IMVT-1402 in Graves' Disease, supported by a $543.7 million offering in December 2025.